TNP-470 antiangiogenic therapy for advanced murine neuroblastoma

The finding that angiogenesis plays an important role in the progression and metastasis of malignant tumors has led to the development of several antiangiogenic drugs. The authors report here an examination of the effect of the antiangiogenic agent TNP-470 on the growth, metastases, and survival of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pediatric surgery 1997-02, Vol.32 (2), p.287-293
Main Authors: Nagabuchi, Eisuke, VanderKolk, Wayne E, Une, Yoshie, Ziegler, Moritz M
Format: Article
Language:English
Subjects:
Animals
Antibiotics, Antineoplastic - therapeutic use
Cyclohexanes
Male
Mice
Mice, Inbred Strains
Neovascularization, Pathologic - drug therapy
Neuroblastoma - drug therapy
Neuroblastoma - pathology
Neuroblastoma - secondary
O-(Chloroacetylcarbamoyl)fumagillol
Sesquiterpenes - therapeutic use
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The finding that angiogenesis plays an important role in the progression and metastasis of malignant tumors has led to the development of several antiangiogenic drugs. The authors report here an examination of the effect of the antiangiogenic agent TNP-470 on the growth, metastases, and survival of two differing murine neuroblastoma cell lines, TBJ and C1300. We found that TNP-470 significantly reduced primary tumor volumes in mice injected with either cell line. In addition, antiangiogenic therapy significantly reduced the size of axillary lymph node metastases in both groups as well as decreased the size of liver metastases in mice receiving TBJ neuroblastoma. TNP-470 treatment also improved animal survival. These data suggest that antiangiogenic therapy retards the growth of primary and metastatic murine neuroblastoma. We speculate that antiangiogenic therapy may be a useful therapeutic modality in the treatment of advanced neuroblastoma once side effects and appropriate dosage requirements are determined.
ISSN:0022-3468
1531-5037
DOI:10.1016/S0022-3468(97)90196-2